Login
Israel-Hamas Conflict
Independence Day
Social Media
Formula 1
Motorsports
Donald Trump
World Cup
Floods
Natural Disasters
Property
Cryptocurrency
Wrestling
Artificial Intelligence
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

MedCity News image

News from MedCity News

If you want to know if MedCity News is credible or reliable, look no further. We rank MedCity News as High factuality. Find out more about our methodology here.

Information about MedCity News

Where is MedCity News located?MedCity News's Website

Media Bias Ratings

Average Bias Rating:
Center
Center
byAd Fontes Media
Center
byMedia Bias/Fact Check
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top MedCity News News

Supreme Court endorses Obamacare panel that requires free preventive care
Obamacare · United States

Supreme Court endorses Obamacare panel that requires free preventive care

56% Center coverage: 149 sources
The Supreme Court on Friday rejected a challenge to an Affordable Care Act provision that set up a panel to recommend preventive care services that insurers must provide at no cost to patients.See the Story
With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short
Johnson & Johnson · United States

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

71% Center coverage: 32 sources
Dizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this genetic signature as an earlier line of therapy, but Dizal executives contend their drug offers the potential for better safety and efficacy. The post With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short appe…See the Story
AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline
Cancer

AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline

87% Center coverage: 8 sources
AbbVie is acquiring Capstan Therapeutics, a startup with technology that enables in vivo engineering of immune cells. The University of Pennsylvania spinout’s lead program recently began a Phase 1 test as a potential treatment for B cell-mediated autoimmune disorders. The post AbbVie’s $2.1B Acquisition Adds In Vivo Cell Therapy to Its Immunology & Inflammation Pipeline appeared first on MedCity News.See the Story

AI Spots Deadly Heart Risk Most Doctors Can't See

100% Center coverage: 6 sources
An advanced Johns Hopkins AI model called MAARS combs through underused heart MRI scans and complete medical records to spot hidden scar patterns that signal sudden cardiac death, dramatically outperforming current dice-roll clinical guidelines and promising to save lives while sparing patients unnecessary defibrillators.Artificial IntelligenceSee the Story

New Bispecific T-Cell Engager Approved for Multiple Myeloma

83% Center coverage: 6 sources
(MedPage Today) -- The FDA on Wednesday granted accelerated approval to linvoseltamab (Lynozyfic) for relapsed or refractory multiple myeloma after at least four prior lines of therapy. A B-cell maturation antigen (BCMA)-directed bispecific antibody...Cancer · United StatesSee the Story

From Fee-for-Service to Value-Based Care: Enhancing Outcomes in Nephrology

100% Center coverage: 1 sources
A systemic change from FFS to VBC would represent more than a payment model switch, but rather a holistic transition toward patient-centered healthcare that prioritizes outcomes over activity. The post From Fee-for-Service to Value-Based Care: Enhancing Outcomes in Nephrology  appeared first on MedCity News.See the Story

From Magic Bullets to Medical Insights: How RFK Jr.'s Critique Shapes the Future of Pharma Advertising

100% Center coverage: 1 sources
But where do truth and trust originate in healthcare marketing? They emerge from various sources such as digital advertising, educational campaigns, patient journeys, and partnerships with healthcare providers who uphold truth in advertising standards.  The post From Magic Bullets to Medical Insights: How RFK Jr.’s Critique Shapes the Future of Pharma Advertising  appeared first on MedCity News.Read Article

From Hype to Impact: How Pharma Can Use Agentic AI to Drive Efficiency and Trust

100% Center coverage: 1 sources
Success with agentic AI won’t come from racing to adopt the flashiest tools. It will come from strategic alignment, understanding where AI can create real value, mitigating risk through thoughtful implementation, and ensuring transparency and oversight at every step. The post From Hype to Impact: How Pharma Can Use Agentic AI to Drive Efficiency and Trust appeared first on MedCity News.Artificial IntelligenceSee the Story

Nordic Capital Acquires Arcadia, Entering the VBC Space

100% Center coverage: 1 sources
Nordic Capital acquired a majority stake in health data platform Arcadia. Together, the two aim to accelerate the company’s mission of advancing value-based care through AI and data analytics. Arcadia CEO Michael Meucci views the deal as both a validation of the company’s strategy and part of a broader wave of healthcare investments focused on interoperability, AI and payment reform. The post Nordic Capital Acquires Arcadia, Entering the VBC Spa…Artificial IntelligenceRead Article

Industry Pressures and Possibilities: What’s Ahead for Skilled Nursing Facilities

100% Center coverage: 1 sources
To remain resilient amid the volatility, skilled nursing facilities s need to stay on top of what’s impacting operations and consider strategic opportunities. Here are important trends to watch.  The post Industry Pressures and Possibilities: What’s Ahead for Skilled Nursing Facilities appeared first on MedCity News.See the Story

Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test

100% Center coverage: 3 sources
Organon said OG-6219 did not beat a placebo in a mid-stage clinical trial whose main goal was to measure the change in pelvic pain caused by endometriosis. The twice-daily pill came from Organon’s 2021 acquisition of Forendo Pharma. The post Organon Stops Work on Endometriosis Drug After Failure in Phase 2 Test appeared first on MedCity News.PharmaSee the Story

Breaking News Topics Related to MedCity News

Health icon

Health

Medical icon

Medical

United States icon

United States

Artificial Intelligence icon

Artificial Intelligence

News
For You
SearchBlindspotLocal